Theseus Pharmaceuticals Inc
NASDAQ:THRX
Intrinsic Value
Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of THRX.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Theseus Pharmaceuticals Inc's business.
What risks and challenges
does Theseus Pharmaceuticals Inc face in the near future?
Summarize the latest earnings report
of Theseus Pharmaceuticals Inc.
Provide P/E
for Theseus Pharmaceuticals Inc and its competitors.
Balance Sheet Decomposition
Theseus Pharmaceuticals Inc
Current Assets | 209.6m |
Cash & Short-Term Investments | 205.1m |
Other Current Assets | 4.5m |
Non-Current Assets | 25m |
Long-Term Investments | 20.3m |
PP&E | 4.3m |
Other Non-Current Assets | 400k |
Current Liabilities | 7m |
Accounts Payable | 1.3m |
Accrued Liabilities | 5.3m |
Other Current Liabilities | 400k |
Non-Current Liabilities | 3.1m |
Other Non-Current Liabilities | 3.1m |
Earnings Waterfall
Theseus Pharmaceuticals Inc
Revenue
|
0
USD
|
Operating Expenses
|
-66.5m
USD
|
Operating Income
|
-66.5m
USD
|
Other Expenses
|
9.9m
USD
|
Net Income
|
-56.6m
USD
|
Free Cash Flow Analysis
Theseus Pharmaceuticals Inc
What is Free Cash Flow?
THRX Profitability Score
Profitability Due Diligence
Theseus Pharmaceuticals Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Theseus Pharmaceuticals Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
THRX Solvency Score
Solvency Due Diligence
Theseus Pharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Theseus Pharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
THRX Price Targets Summary
Theseus Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for THRX is 5.25 USD .
Ownership
THRX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
THRX Price
Theseus Pharmaceuticals Inc
Average Annual Return | -46.28% |
Standard Deviation of Annual Returns | 12.78% |
Max Drawdown | -89% |
Market Capitalization | 177m USD |
Shares Outstanding | 44 649 200 |
Percentage of Shares Shorted | 1.91% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. The company is headquartered in Cambridge, Massachusetts and currently employs 26 full-time employees. The company went IPO on 2021-10-07. The firm is focused on treating cancer patients through the discovery, development and commercialization of targeted therapies. Its development programs are designed to address drug resistance mutations in oncogenes, which are mutated genes that cause cancer. The firm is focused on developing tyrosine kinase inhibitors (TKI), which is rooted in the critical role that tyrosine kinases play in the development of cancer. The company is focused to development of pan-variant kinase inhibitors that target all cancer causing and drug resistance mutations in clinically protein kinases. The firm's product candidate, THE-630, is a pan-variant inhibitor of all classes of activating and resistance mutations of the KIT kinase, or a pan-KIT inhibitor, for the treatment of gastrointestinal stromal tumors (GIST), a type of cancer characterized by oncogenic activation of KIT.